Cefix (cefixime) suspension powder 100 mg/5 ml. 30 ml.

Description

Infectious-inflammatory diseases caused by susceptible microorganisms:
upper respiratory tract infections (including middle ear inflammation) and other upper respiratory tract infections (sinusitis, pharyngitis, tonsillitis bacterial etiology) in the case of known or suspected pathogen resistance to other commonly used antibiotics, or in cases of risk;
lower respiratory tract infections (including acute bronchitis and exacerbation of chronic bronchitis);
urinary tract infections (including cystitis, cystourethritis, uncomplicated pyelonephritis).
Clinically effective in the treatment of infections caused by the most common pathogens, including Streptococcus pneumoniae, Streptococcus pyogenes, E.coli, Proteus Mirabilis, Klebsiella species, Haemophilus influenzae (beta-lactamazpositive and -negative) negative) and Enterobacter species. Has a high degree of stability in the presence of beta-lactamases.
Most strains of enterococci (Streptococcus faecalis, group D Streptococci) and Staphylococci (including coagulase-positive, coagulase-negative and methicillin-resistant strains) are resistant to cefixime. In addition, most strains of Pseudomonas, Bacteroides fragilis, Listeria monocytogenes and Clostridia are resistant to cefixime.